Patents Assigned to Children's Hospital Medical Center of Cincinnati, Ohio
  • Patent number: 8450364
    Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: May 28, 2013
    Assignees: Brigham Young University, Colorado State University Research Foundation, Children's Hospital Medical Center of Cincinnati, Ohio
    Inventors: Edwin Douglas Lephart, Trent D. Lund, Kenneth David Reginald Setchell, Robert J. Handa
  • Patent number: 8153684
    Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: April 10, 2012
    Assignees: Colorado State University Research Foundation, Brigham Young University Technology Transfer Office, Children's Hospital Medical Center of Cincinnati, Ohio
    Inventors: Edwin Douglas Lephart, Trent D. Lund, Kenneth David Reginald Setchell, Robert J. Handa